Very quickly, I think I would look to ensure that the progressive licences are only used in circumstances that are extremely dire, in which there are compelling and compassionate grounds for making access to a medicine early, on the basis of compassion. Making access to yet another drug to manage cholesterol faster in the name of access to medicines is not necessarily, in my opinion, appropriate. So I would look for that, and I would also look for the double edge of this rapid access, which would be to ensure a greater amount of transparency.
If a manufacturer is going to bring a product to market with little or no evidence of effectiveness, whatever evidence it has, no matter how commercially important it is to the manufacturer, it is asking Canadians to effectively be guinea pigs, and therefore Canadians ought to have access to every piece of trial data that was submitted to Health Canada.